Gunzburg announced an imminent clinical trial of a "cocktail of antibodies"

The Gamaleya Center should soon receive permission to conduct clinical trials of a drug for coronavirus based on monoclonal antibodies. This was announced by the director of the center Alexander Gintsburg, RIA Novosti reports.

“A package of documents for obtaining permission for clinical trials has been submitted. As far as I know, permission should be obtained soon,” he said.

Monoclonal antibodies are produced by immune cells that originate from a single progenitor plasma cell.

Preparations based on them are used to treat migraine, melanoma, and breast cancer.

Gunzburg announced the creation of drugs for coronavirus in December 2020. Then he said that he would be used for droppers. Patients should develop antibodies after one or two doses of the drug. They will circulate in the blood for seven to 10 days or longer, the director of the center noted.

How the number of hospitalizations with coronavirus in Russia is changing February 15 The number of hospitalized and diagnosed cases per day. The operational headquarters began to provide open regular statistics on hospitalizations from January 20, 2022 Created with Highcharts 8.2.2

See also Who will pay for the non-working week 01:23